# | Title | Journal | Year | Citations |
---|
1 | Albumin-bound paclitaxel: a next-generation taxane | Expert Opinion on Pharmacotherapy | 2006 | 569 |
2 | Toxicity of platinum compounds | Expert Opinion on Pharmacotherapy | 2003 | 466 |
3 | Paclitaxel in cancer therapy | Expert Opinion on Pharmacotherapy | 2002 | 301 |
4 | Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control | Expert Opinion on Pharmacotherapy | 2004 | 289 |
5 | Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management | Expert Opinion on Pharmacotherapy | 2007 | 271 |
6 | Review of sertraline and its clinical applications in psychiatric disorders | Expert Opinion on Pharmacotherapy | 2001 | 267 |
7 | Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches | Expert Opinion on Pharmacotherapy | 2014 | 259 |
8 | Zolpidem for insomnia | Expert Opinion on Pharmacotherapy | 2012 | 258 |
9 | Donepezil: an update | Expert Opinion on Pharmacotherapy | 2007 | 235 |
10 | Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review | Expert Opinion on Pharmacotherapy | 2015 | 218 |
11 | Opinion on the diagnosis and treatment of human trichinellosis | Expert Opinion on Pharmacotherapy | 2002 | 215 |
12 | Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study | Expert Opinion on Pharmacotherapy | 2010 | 214 |
13 | An update on pharmacotherapy for leishmaniasis | Expert Opinion on Pharmacotherapy | 2015 | 213 |
14 | Opioid dependence treatment: options in pharmacotherapy | Expert Opinion on Pharmacotherapy | 2009 | 211 |
15 | Leishmaniasis: an update of current pharmacotherapy | Expert Opinion on Pharmacotherapy | 2013 | 207 |
16 | Reboxetine: the first selective noradrenaline re-uptake inhibitor | Expert Opinion on Pharmacotherapy | 2000 | 202 |
17 | The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review | Expert Opinion on Pharmacotherapy | 2009 | 193 |
18 | Iloperidone, asenapine and lurasidone: a primer on their current status | Expert Opinion on Pharmacotherapy | 2012 | 189 |
19 | An update on chemotherapy for osteosarcoma | Expert Opinion on Pharmacotherapy | 2015 | 187 |
20 | Levetiracetam: treatment in epilepsy | Expert Opinion on Pharmacotherapy | 2003 | 186 |
21 | Photodynamic therapy in oncology | Expert Opinion on Pharmacotherapy | 2001 | 184 |
22 | Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? | Expert Opinion on Pharmacotherapy | 2007 | 180 |
23 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? | Expert Opinion on Pharmacotherapy | 2010 | 179 |
24 | Long-term use of sildenafil | Expert Opinion on Pharmacotherapy | 2003 | 178 |
25 | Paroxetine for the treatment of depression: a critical update | Expert Opinion on Pharmacotherapy | 2012 | 176 |
26 | Treatment strategies underpinning the global programme to eliminate lymphatic filariasis | Expert Opinion on Pharmacotherapy | 2005 | 175 |
27 | An assessment of zonisamide as an anti-epileptic drug | Expert Opinion on Pharmacotherapy | 2000 | 172 |
28 | Ribavirin - current status of a broad spectrum antiviral agent | Expert Opinion on Pharmacotherapy | 2001 | 169 |
29 | Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer | Expert Opinion on Pharmacotherapy | 2009 | 165 |
30 | Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer’s disease? | Expert Opinion on Pharmacotherapy | 2003 | 164 |
31 | Carbapenems: a potent class of antibiotics | Expert Opinion on Pharmacotherapy | 2008 | 159 |
32 | Diagnosis and treatment of vitamin D deficiency | Expert Opinion on Pharmacotherapy | 2008 | 156 |
33 | Pharmacotherapy for dyslipidaemia – current therapies and future agents | Expert Opinion on Pharmacotherapy | 2003 | 154 |
34 | Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials | Expert Opinion on Pharmacotherapy | 2015 | 152 |
35 | Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease | Expert Opinion on Pharmacotherapy | 2009 | 151 |
36 | New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease | Expert Opinion on Pharmacotherapy | 2014 | 150 |
37 | Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial | Expert Opinion on Pharmacotherapy | 2009 | 147 |
38 | The use of cephalosporins for gonorrhea: the impending problem of resistance | Expert Opinion on Pharmacotherapy | 2009 | 147 |
39 | Treatment ofAcinetobacterinfections | Expert Opinion on Pharmacotherapy | 2010 | 146 |
40 | Efficacy of α-lipoic acid in diabetic neuropathy | Expert Opinion on Pharmacotherapy | 2014 | 139 |
41 | Treatment of central sensitization in patients with ‘unexplained’ chronic pain: an update | Expert Opinion on Pharmacotherapy | 2014 | 138 |
42 | The economic burden of depression in the US: societal and patient perspectives | Expert Opinion on Pharmacotherapy | 2005 | 135 |
43 | Antimicrobial peptides: therapeutic potential | Expert Opinion on Pharmacotherapy | 2006 | 135 |
44 | Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? | Expert Opinion on Pharmacotherapy | 2016 | 135 |
45 | Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias | Expert Opinion on Pharmacotherapy | 2000 | 134 |
46 | An update on the medical management of listeriosis | Expert Opinion on Pharmacotherapy | 2004 | 134 |
47 | Sorafenib: a clinical and pharmacologic review | Expert Opinion on Pharmacotherapy | 2010 | 131 |
48 | Ziconotide: an update and review | Expert Opinion on Pharmacotherapy | 2008 | 129 |
49 | Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain | Expert Opinion on Pharmacotherapy | 2006 | 128 |
50 | Colon cancer: preventive agents and the present status of chemoprevention | Expert Opinion on Pharmacotherapy | 2009 | 128 |